Canadian drug safety network provides reassuring evidence regarding risk of heart failure of anti-diabetes medications
Incretin-based drugs, a type of medication used to treat type 2 diabetes, do not increase the risk of being hospitalized for heart failure relative to commonly used combinations of oral anti-diabetic drugs, according to a new study published in the New England Journal of Medicine.
The use of incretin-based drugs is not associated with an increased risk of pancreatic cancer in patients with type 2 diabetes, according to a study published in the latest issue of the British Medical Journal (BMJ).
The research was conducted by the Canadian Network for Observational Drug Effect Studies (CNODES), which used the health records of almost 1 million patients with types 2 diabetes.
The discovery that tavilermide induces the production of mucin, a crucial lubricant in tears, offers hope of relief to people who suffer from chronic dry eye disease. The invention and the development of a drug based on this small molecule was made by the team of Dr. H. Uri Saragovi, Senior Investigator at the Lady Davis Institute (LDI) at the Jewish General Hospital and Professor of Pharmacology at McGill University.